All News

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim analysis and potential regulatory approvals.

Replacing transplant and chemo with CI-based therapy and ISRT maintains survival, reduces side effects in younger patients with classic Hodgkin lymphoma.

The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1.

Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and less immune suppression.

Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a risk of new onset psoriasis.

Being diagnosed with colon cancer at 34 was difficult, but choosing happiness and acceptance helped me find peace through mindfulness, nature and family.

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted in positive responses.

The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.

The first patient has been dosed in a first-in-human clinical trial evaluating HLD-0915 for metastatic castration-resistant prostate cancer.

Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.

Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer.

Treatment with the CAR T-cell therapy cema-cel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphoma.

Chemoradiation improves survival in cervical cancer patients, but benefits may decline after age 80, according to a study using SEER data.

A year ago, I was told my lymphoma had worsened, but a miraculous turn of events spared me from aggressive chemotherapy, making me grateful for each day of life.

Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.

For female patients with glioma, pregnancy after receiving a diagnosis of glioma is associated with worse progression-free survival times.

Dr. Chandler Park helps patients with genitourinary cancers, including both prostate and bladder, understand the importance of genetic testing.

Fractionated reirradiation is safe and feasible, suggesting higher reirradiation dose may be feasible in patients with recurrent high-grade glioma.

The addition of ctDNA testing to radiographic surveillance resulted in curative surgical intervention for 1.6% of patients with colorectal cancer.

After realizing that a stronger support system would have helped me emotionally and spiritually in my cancer journey, I committed myself to being there for my cousin.

Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic alterations, including EGFR and ALK subgroups.

Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative metastatic breast cancer.

Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.

There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.

Being a young adult cancer survivor is bittersweet, bringing both unique struggles and unexpected blessings that shape my life, career and perspective.

Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and monitoring based on disease characteristics.